低剂量秋水仙碱用于冠心病二级预防:JACC综述
在已接受他汀治疗的患者中,高敏C反应蛋白评估的炎症对心血管死亡和全因死亡的预测力强于低密度脂蛋白胆固醇。低剂量秋水仙碱(0.5 mg/d口服)在稳定动脉粥样硬化患者中降低主要不良心血管事件31%,近期心肌梗死后降低23%。2023年6月FDA批准低剂量秋水仙碱用于已确诊动脉粥样硬化或有多重心血管危险因素的成人,以降低心梗、卒中、冠脉血运重建和心血管死亡风险。
要点
- 他汀治疗患者中,hsCRP评估的炎症比LDL-C更能预测心血管死亡和全因死亡。
- 低剂量秋水仙碱0.5 mg/d口服可安全降低稳定动脉粥样硬化患者MACE 31%。
- 近期心梗后使用低剂量秋水仙碱可降低MACE 23%,效益大于附加降脂药试验。
核心结论
- 在指南导向药物治疗(含他汀)的冠心病患者中,低剂量秋水仙碱可安全降低主要不良心血管事件。
- 降脂与抗炎治疗并不冲突而是协同,未来联合强化降LDL-C与抗炎治疗可能成为多数动脉粥样硬化患者的标准治疗。
研究设计与样本
- JACC综述,汇总他汀治疗患者中炎症标志物预测价值及低剂量秋水仙碱二级预防证据。
主要发现
- 他汀治疗患者中,hsCRP评估的炎症对心血管死亡和全因死亡的预测力强于LDL-C。
- 低剂量秋水仙碱(0.5 mg/d口服)在稳定动脉粥样硬化患者中降低主要不良心血管事件31%。
- 近期心肌梗死后使用低剂量秋水仙碱降低主要不良心血管事件23%。
- 上述获益幅度大于当代附加降脂药的二级预防试验。
关键数值与推荐
- 低剂量秋水仙碱推荐口服剂量为0.5 mg/d。
- 显著肾功能或肝功能不全患者禁用低剂量秋水仙碱。
- 与克拉霉素、酮康唑、环孢素等共享代谢途径的药物合用时,应暂时停用低剂量秋水仙碱。
- 2023年6月FDA批准低剂量秋水仙碱用于已确诊动脉粥样硬化或有多重心血管危险因素的成人,以降低心梗、卒中、冠脉血运重建和心血管死亡风险。
临床怎么用
- 对已接受指南导向药物治疗(含他汀)的冠心病患者,可考虑加用低剂量秋水仙碱0.5 mg/d以降低MACE。
- 使用前评估肾功能和肝功能,显著异常者禁用。
- 与克拉霉素、酮康唑、环孢素等药物合用时暂时停用低剂量秋水仙碱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Among statin-treated patients, inflammation assessed by means of high-sensitivity C-reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all-cause mortality than low-density-lipoprotein cholesterol (LDL-C). Several therapies that target residual inflammatory risk significantly reduce vascular event rates. For coronary artery disease patients already taking guideline-directed medical care, including statins, low-dose colchicine (0.5 mg/d orally) has been shown to safely lower major adverse cardiovascular events by 31% among those with stable atherosclerosis and by 23% after recent myocardial infarction. These magnitudes of benefit are larger than those seen in contemporary secondary prevention trials of adjunctive lipid-lowering agents. Low-dose colchicine is contraindicated in patients with significant renal or liver dysfunction and should be temporarily discontinued when taking concomitant agents such as clarithromycin, ketoconazole, and cyclosporine that share metabolism pathways. Lipid lowering and inflammation inhibition are not in conflict but are synergistic. In the future, combined use of aggressive LDL-C-lowering and inflammation-inhibiting therapies may become standard of care for most atherosclerosis patients. In June 2023, the U.S. Food and Drug Administration approved the use of low-dose colchicine to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.
引用
- Nelson K, Fuster V, Ridker PM, et al. Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2023. PMID: 37558377. doi:10.1016/j.jacc.2023.05.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。